Review of risedronate in the treatment of osteoporosis

Bibliography

• Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organisation Technical Report Series (1994) 843.
   Google Scholar
• ••Extensive WHO report on osteoporosis.
   Google Scholar
• KANIS JA, GLUER CC: An update on thediagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos. Irk (2000) 11:192–202.
   PubMed Web of Science ®Google Scholar
• ••Extensive report of the InternationalOsteoporosis Foundation on diagnosis of osteoporosis.
   Google Scholar
• MELTON LJ 3RD, CHRISCHILLES EA, COOPER C, LANE AW, RIGGS BL: Perspective. How many women have osteoporosis? j Bone Miter. Res. (1992) 7:1005–1010.
   PubMed Web of Science ®Google Scholar
• RODAN GA, MARTIN TJ: Therapeutic approaches to bone diseases. Science (2000) 289:1508–1514.
   PubMed Web of Science ®Google Scholar
• ••Recent overview of therapeutic options.
   Google Scholar
• WATTS NB, HARRIS ST, GENANT HK et al.: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl. j Med. (1990) 323:73–79.
   PubMed Web of Science ®Google Scholar
• •Study using etidronate with fracture prevention results in post hoc analysis.
   Google Scholar
• HARRIS ST, WATTS NB, JACKSON RD et al.: Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am. J. Med. (1993) 95:557–567.
   PubMed Web of Science ®Google Scholar
• CRANNEY A, GUYATT G, KROLICKI N et al.: Osteoporosis Research Advisory Group (ORAG). A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos. Int. (2001) 12:140–151
   PubMed Web of Science ®Google Scholar
• LIBERMAN UA, WEISS SR, BROLL J et al.: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl. J. Med. (1995) 333:1437–1443.
   PubMed Web of Science ®Google Scholar
• BLACK DM, CUMMINGS SR, KARPF DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. (1996) 348:1535–1541.
   PubMed Web of Science ®Google Scholar
• ••First large scale study using alendronatewith incidence of fractures as a primary end point.
   Google Scholar
• CUMMINGS SR, BLACK DM, THOMPSON DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. (1998) 280:2077–2082.
   PubMed Web of Science ®Google Scholar
• ••First large scale study with alendronate toprevent first fracture.
   Google Scholar
• BLACK DM, THOMPSON DE, BAUER DC et al.: Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab. (2000) 85:4118–4124.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis of two arms of the FIT with alendronate.
   Google Scholar
• POLS HA, FELSENBERG D, HANLEY DA et al.: Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos. Irk (1999) 9:461–468.
   PubMed Web of Science ®Google Scholar
• •Early effect with alendronate to prevent non-vertebral fractures.
   Google Scholar
• ENSRUD KE, BLACK DM, PALERMO L et al: Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch. Intern. Med. (1997) 157:2617–2624.
   PubMed Web of Science ®Google Scholar
• NEVITT MC, THOMPSON DE, BLACK DM et al.: Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch. Intern. Med. (2000) 160:77–85.
   PubMed Web of Science ®Google Scholar
• ••Effect of alendronate on quality of life.
   Google Scholar
• SCHNITZER T, BONE HG, CREPALDI G et al: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (klilano) (2000) 12:1–12.
   Google Scholar
• CRANDALL C: Risedronate: a clinical review. Arch. Intern. Med. (2001) 161:353–360.
   Google Scholar
• DUNN CJ, GOA KL: Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs. (2001) 61:685–712.
   PubMedGoogle Scholar
• GOA KL, BALFOUR JA: Risedronate. Drugs Aging. (1998) 13:83–91.
   PubMedGoogle Scholar
• RUSSELL RG, ROGERS MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone (1999) 25:97–106.
   PubMed Web of Science ®Google Scholar
• ••Extensive and clear description ofbisphosphonates in metabolic bone diseases.
   Google Scholar
• WRONSKI TJ, YEN CF, SCOTT KS: Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J. Bone Miner. Res. (1991) 6:387–394.
   PubMed Web of Science ®Google Scholar
• GEDDES AD, D'SOUZA SM, EBETINOFH, IBBOTSON KJ: Bisphosphonates: structure-activity relationships and therapeutic implications. In: Bone, and Mineral Research 8: A Regular Survey of Developments in the Field of Bone, and Mineral Metabolism. Heersche JNM and Kanis JA (Eds.), Elsevier, Amsterdam (1994):265–306.
   Google Scholar
• VAN BEEK ER, LOWIK CW, EBETINO FH, PAPAPOULOS SE: Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone (1998) 23:437–442.
   PubMed Web of Science ®Google Scholar
• LUCKMAN SP, COXON FP, EBETINO FH, RUSSELL RG, ROGERS MJ: Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner. Res. (1998) 13:1668–1678.
   PubMed Web of Science ®Google Scholar
• BOISSIER S, MAGNETTO S, FRAPPART L et al.: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. (1997) 57:3890–3894.
   PubMed Web of Science ®Google Scholar
• MOSEKILDE L, THOMSEN JS, MACKEY MS, PHIPPS RJ: Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone (2000) 27:639–645.
   PubMed Web of Science ®Google Scholar
• WRONSKI TJ, YEN CF, SCOTT KS: Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J. Bone It/liner Res. (1991) 6:387–394.
   PubMed Web of Science ®Google Scholar
• LI QN, LIANG NC, HUANG LF, WU T, HU B, MO LE: Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats. J. Bone It/liner Metab. (1999) 17:18–22.
   PubMed Web of Science ®Google Scholar
• BOYCE RW, WRONSKI TJ, EBERT DC et al.: Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. Bone (1995) 16:209–213.
   Google Scholar
• JEE WS, TANG L, KE HZ, SETTERBERG RB, KIMMEL DB: Maintaining restored bone with bisphosphonate in the ovariectomized rat skeleton: dynamic histomorphometry of changes in bone mass. Bone (1993) 14:493–498.
   Google Scholar
• BOYCE RW, PADDOCK CL, GLEASON JR, SLETSEMA WK, ERIKSEN EF: The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J. Bone Miner. Res. (1995) 10:211–221.
   PubMed Web of Science ®Google Scholar
• ADACHI H, IGARASHI K, MITANI H, SHINODA H: Effects of topical administration of a bisphosphonate (risedronate) on orthodontic tooth movements in rats. J. Dent. Res. (1994) 73:1478–1486.
   PubMed Web of Science ®Google Scholar
• SHOJI K, HORIUCHI H, SHINODA H: Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J. Periodontal. Res. (1995) 30:277–284.
   PubMed Web of Science ®Google Scholar
• IGARASHI K, ADACHI H, MITANI H, SHINODA H: Inhibitory effect of the topical administration of a bisphosphonate (risedronate) on root resorption incident to orthodontic tooth movement in rats. J. Dent. Res. (1996) 75:1644–1649.
   PubMed Web of Science ®Google Scholar
• BOISSIER S, FERRERAS M, PEYRUCHAUD 0, MAGNETTO S, EBETINO FH, COLOMBEL M etal.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. (2000) 60:2949–2954
   Google Scholar
• SASAKI A, BOYCE BF, STORY B, WRIGHT KR, CHAPMAN M, BOYCE R et al.: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. (1995) 55:3551–3557.
   PubMed Web of Science ®Google Scholar
• HALL DG, STOICA G: Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J. Bone Miner. Res. (1994) 9:221–230.
   PubMed Web of Science ®Google Scholar
• FLEISCH H: Bisphosphonates: mechanisms of action. Endocr. Rev (1998) 19:80–100.
   PubMed Web of Science ®Google Scholar
• ••Extensive overview of several aspects ofmechanisms of action of bisphosphonates.
   Google Scholar
• LUCKMAN SP, HUGHES DE, COXON FP, GRAHAM R, RUSSELL G, ROGERS MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. (1998) 13:581–589.
   PubMed Web of Science ®Google Scholar
• VAN BEEK ER, LOWIK CW, EBETINO FH, PAPAPOULOS SE: Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone (1998) 23:437–442.
   PubMed Web of Science ®Google Scholar
• VAN BEEK E, LOWIK C, VAN DER PLUIJM G, PAPAPOULOS S: The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. j Bone Nliner. Res. (1999) 14:722–729.
   PubMed Web of Science ®Google Scholar
• VAN BEEK E, PIETERMAN E, COHEN L, LOWIK C, PAPAPOULOS S: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. (1999) 264:108–111.
   PubMed Web of Science ®Google Scholar
• FISHER JE, RODAN GA, RESZKA AA: In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology (2000) 141:4793–4796.
   PubMed Web of Science ®Google Scholar
• GROVE JE, BROWN RJ, WATTS DJ: The intracellular target for the antiresorptive aminobisphosphonate drugs in dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. I Bone Miner. Res. (2000) 15:971–981.
   Google Scholar
• COXON FP, HELFRICH MH, VAN'T HOF R et al.: Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. (2000) 15:1467–1476.
   Google Scholar
• DUNFORD JE, THOMPSON K, COXON FP et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. I Pharmacol. Exp. Ther (2001) 296:235–242.
   PubMed Web of Science ®Google Scholar
• HUGHES DE, WRIGHT KR, UY HL et al.: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miler. Res. (1995) 10:1478–1487.
   PubMed Web of Science ®Google Scholar
• RESZKA AA, HALASY-NAGY JM, MASARACHIA PJ, RODAN GA: Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mstl kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J. Biol. Chem. (1999) 274:34967–34973.
   Google Scholar
• EBETINO FH, FRANCIS MD, ROGERS MJ, RUSSELL RGG: Mechanisms of action of etidronate and other bisphosphonates. Rev. Contemp. Pharmacother (1998) 9:233–243
   Web of Science ®Google Scholar
• HARRIS ST, WATTS NB, GENANT HK et al.: Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. (1999) 282:1344–1352.
   Google Scholar
• ••First large scale study using risedronatewith incidence of fractures as a primary end point.
   Google Scholar
• REGINSTER J, MINNE HW, SORENSEN OH etal.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. (2000) 11:83–91.
   Google Scholar
• COHEN S, LEVY RIVI, KELLER M et al.:Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multi- centre, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. (1999) 42:2309-2318. Effect of risedronate in prevention of GIO.
   Google Scholar
• REID DM, HUGHES RA, LAAN RF et al.: Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miler. Res. (2000) 15:1006–1013.
   PubMed Web of Science ®Google Scholar
• ••Effect of risedronate in treatment of GIO.
   Google Scholar
• WALLACH S, COHEN S, REID DM et al.: Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Cairn: Tissue Int. (2000) 67:277–285.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis of risedronate in GIO.
   Google Scholar
• ROUX C, RAVAUD P, COHEN-SOLAL M et al.: Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone (1994) 15:41–49.
   PubMed Web of Science ®Google Scholar
• ERIKSON EE BROWN JP, BOLING E et al: Beneficial effects of risedronate in corticosteroid-treated patients: histology and histomorphometry (abstract). Bone (1998) 23(Suppl.):5403. Abstract.
   Google Scholar
• BOIVIN GY, CHAVASSIEUX PM, SANTORA AC, YATES J, MEUNIER PJ: Alendronate increases bone strength by increasing the mean degree of mineralisation of bone tissue in osteoporotic women. Bone (2000) 27:687–694.
   PubMed Web of Science ®Google Scholar
• ••New insights in the mechanisms of actionof bisphosphonates on bone.
   Google Scholar
• MITCHELL DY, EUSEBIO RA, SACCO-GIBSON NA et al.: Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J. Clin. Pharmacol. (2000) 40:258–265.
   PubMed Web of Science ®Google Scholar
• MITCHELL DY, HEISE MA, PALLONE KA et al.: The effect of dosing regimen on the pharmacokinetics of risedronate. Br. J. Pharmacol. (1999) 48:536–542.
   Google Scholar
• MITCHELL DY, BARR WH, EUSEBIO RA etal.: Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm. Res. (2001) 18:166–170.
   Google Scholar
• MITCHELL DY, ST PETER JV, EUSEBIO RA etal.: Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J. Clin. Pharmacol. (2000) 49:215-222. Expert Op/n. Pharmacother. (2001) 2(12)
   Google Scholar
• MITCHELL DY, EUSEBIO RA, DUNLAP LE et al: Risedronate gastrointestinal absorption is independent of site and rate of administration. Pharm. Res. (1998) 15:228–232.
   PubMed Web of Science ®Google Scholar
• SMITH BJ, HU JK, SCHWECKE WP: Evaluation of the effects of risedronate on hepatic microsomal drug metabolising enzyme activities following administration to rats for 14 days: lack of an induction response. Drug Chem. Taxied. (1998) 21:291–303.
   PubMed Web of Science ®Google Scholar
• CUMMINGS SR, NEVITT MC, BROWNER WS et al.: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl. J. Med. (1995) 332:767–773.
   PubMed Web of Science ®Google Scholar
• ••Clinical study about skeletal and non-skeletal risk factors for hip fracture.
   Google Scholar
• LINDSAY R, SILVERMAN SL, COOPER C et al.: Risk of new vertebral fracture in the year following a fracture. JAMA. (2001) 285:320–323.
   PubMed Web of Science ®Google Scholar
• ••Clinical dynamics of osteoporosis.
   Google Scholar
• GARNERO P, HAUSHERR E, CHAPUY MC et al: Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J. Bone Miner Res. (1996) 11:1531–1538.
   PubMed Web of Science ®Google Scholar
• ••Importance of bone turnover as an independent risk factor for fractures.
   Google Scholar
• MARSHALL D, JOHNELL 0, WEDEL H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med. J. (1996) 312:1254–1259.
   PubMed Web of Science ®Google Scholar
• ••Meta-analysis on the value of bonedensitometry in the prediction of fractures.
   Google Scholar
• DE LAET CE, VAN HOUT BA, BURGER H, WEEL AE, HOFMAN A, POLS HA: Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J. Bone Miner Res. (1998) 13:1587–1593.
   PubMed Web of Science ®Google Scholar
• HAYES WC, MYERS ER: Biomechanics of fractures. In: Osteoporosis. Riggs BL, Melton LJ (Eds.), New York: Raven Press (1995):93–114.
   Google Scholar
• HINDMARSH JJ, ESTERS EH: Falls in older patients: causes and interventions. Arch. Intern. Med. (1989) 149:2217–2222.
   PubMed Web of Science ®Google Scholar
• PROVINCE M, HADLEY E, HORNBROOK M et al: The effect of exercise on falls in elderly patients. JAMA (1995) 273:1341–1447.
   PubMed Web of Science ®Google Scholar
• TINETTI M, BAKER D, MCAVAY G et al: A multifactorial intervention to reduce the risk of falling among elderly people in the community. N Engl. J. Med. (1994) 331:821–827.
   PubMed Web of Science ®Google Scholar
• WOLF SL, BARNHART HX, KUTNER NG, MCNEELY E, COOGLER C, XU T: Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and Injuries: Cooperative Studies of Intervention Techniques. J. Am. Ceriatr. Soc. (1996) 44:489–497.
   Google Scholar
• LAURITZEN JB, PETERSEN MM, LUND B: Effect of external hip protectors on hip fractures. Lancet (1993) 341:11–13.
   PubMed Web of Science ®Google Scholar
• ••First study to show the effect of hipprotectors in frail elderly.
   Google Scholar
• KANNUS P, PARKKARI J, NIEMI S etal.: Prevention of hip fracture in elderly people with use of a hip protector. N Engl. J. Med. (2000) 343:1506–1513.
   Google Scholar
• GUYATT G: Evidence-based management of patients with osteoporosis. J. Chu. Densitometry (1998) 1:395–402.
   PubMed Web of Science ®Google Scholar
• ••Stressing the importance of evidence-basedmedicine in practice.
   Google Scholar
• CHAPUY MC, ARLOT ME, DUBOEUF F et al.: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl. J. Med. (1992) 327:1637–1642.
   PubMed Web of Science ®Google Scholar
• •Correcting deficient calcium and vitamin intake reduced hip fracture risk.
   Google Scholar
• REGINSTER JY, MEURMANS L, ZEGELS B et al.: The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann. Intern. Med. (1998) 129:1–8.
   PubMed Web of Science ®Google Scholar
• MEUNIER PJ, SEBERT JL, REGINSTER JY etal.: Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO study. Osteoporos. Irm (1998) 8:4–12.
   Google Scholar
• NEER RM, ARNAUD CD, ZANCHETTA JR et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl. J. Med. (2001) 344:1434–1441
   PubMed Web of Science ®Google Scholar
• ••First study with PTH with fractureincidence as primary end point.
   Google Scholar
• LUFKIN EG, WAHNER HW, O'FALLON WM et al.: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Intern. Med. (1992) 117:1–9.
   Google Scholar
• ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. (1999) 282:637–645.
   Google Scholar
• ••First study with a SERM with fractureincidence as primary end point.
   Google Scholar
• CHESNUT CH 3RD, SILVERMAN S, ANDRIANO K et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med. (2000) 109:267–276.
   Google Scholar
• ••Effect of nasal calcitonin on fracture risk.
   Google Scholar
• MCCLUNG MR, GEUSENS P, MILLER PD et al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl. J. Med. (2001) 344:333–340.
   PubMed Web of Science ®Google Scholar
• ••First study with a bisphosphonate with hipfracture prevention as a primary end point.
   Google Scholar
• HOSKING D et al.: Sustained fracture benefit with five years of risedronate in postmenopausal women. European Calcified Tissue Society, Madrid, June 2001. Bone (2001) 28(5)(Suppl.):5229.
   Google Scholar
• HOOPER M et al.: Sustained effect of Risedronate in the prevention of the first vertebral fracture in women. American Society of Bone and Mineral Research, Toronto, September 2000. _J. Bone Miner Res. (2000), 15\(Suppl. 1):5428. Abstract.
   Google Scholar
• VAN STAA TP, LEUFKENS HG, ABENHAIM L, ZHANG B, COOPER C: Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. (2000) 15:993-1000. GIO is related to an increased fracture risk.
   Google Scholar
• MANOLAGAS SC: Corticosteroids and fractures: a close encounter of the third cell kind. J. Bone Miter. Res. (2000) 15:1001–1005.
   PubMed Web of Science ®Google Scholar
• AMIN S, LAVALLEY MP, SIMMS RW, FELSON DT: The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum. (1999) 42:1740–1751.
   PubMed Web of Science ®Google Scholar
• ADACHI JD, ROUX C, PITT PI et al.: A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J. Rheumatol. (2000) 27:2424–2431.
   Google Scholar
• ••Meta-analysis of the effect of etidronate in GIO.
   Google Scholar
• SAAG KG, EMKEY R, SCHNITZER TJ et al: Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl. J. Med (1998) 339:292–299.
   PubMed Web of Science ®Google Scholar
• ••One-year study of alendronate in GIO.
   Google Scholar
• ADACHI JD, SAAG KG, DELMAS PD et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. (2001) 44:202–211.
   PubMed Web of Science ®Google Scholar
• ••Two-year study of alendronate in GIOwith effect on vertebral fracture prevention.
   Google Scholar
• LINDSAY R et al.: Risedronate 35 mg once a week is as effective as 5 mg daily in postmenopausal women. Arthritis Rheum. (2001) 44(Suppl.):5153.
   Google Scholar
• FORWOOD MR, BURR DB, TAKANO Y, EASTMAN DF, SMITH PN, SCHWARDT JD: Risedronate treatment does not increase microdamage in the canine femoral neck. Bone (1995) 16:643–650.
   Google Scholar
• MASHIBA T, TURNER CH, HIRANO T,FORWOOD MR, JOHNSTON CC, BURR DB: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone (2001) 28:524–31.
   PubMed Web of Science ®Google Scholar
• BROWN JP, HOSKING DJ, STE-MARIE L etal.: Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study. Calcif Tissue Int. (1999) 64:93–99.
   Google Scholar
• BROWN JP, CHINES AA, MYERS WR, EUSEBIO RA, RITTER-HRNCIRIK C, HAYES CW: Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone (2000) 26:263–267.
   PubMedGoogle Scholar
• PETER CI KINDT MV, MAJKA JA: Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig. Dis. Sci. (1998) 43:1009–1015.
   Google Scholar
• LICHTENBERGER LM, ROMERO JJ, GIBSON GW, BLANK MA: Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig. Dis. Sa. (2000) 45:1792–1801.
   PubMed Web of Science ®Google Scholar
• RESZKA AA, HALASY-NAGY J, RODANGA: Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Ma Pharmacol (2001) 59:193–202.
   PubMed Web of Science ®Google Scholar
• PETER CP, HANDT LK, SMITH SM: Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig. Dis. Sci. (1999) 43:1998–2002.
   Google Scholar
• DE GROEN PC, LUBBE DF, HIRSCH LJ et al.: Esophagitis associated with the use of alendronate. N Engl. J. Med. (1996) 335:1016–1021
   PubMed Web of Science ®Google Scholar
• PERKINS AC, WILSON CG, FRIER M et al.: Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects. Aliment. Pharmacol The]: (2001) 15:115–121.
   PubMed Web of Science ®Google Scholar
• LANZA FL, RACK MF, LI Z, KRAJEWSKI SA, BLANK MA: Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women. Aliment. Pharmacol Ther (2000) 14:1663–1670.
   Google Scholar
• LANZA E SCHWARTZ H, SAHBA B et at.: An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am. j. Gastroenterol (2000) 95:3112–3117.
   Google Scholar
• LANZA FL, HUNT RH, THOMSON AB, PRO VENZA JM, BLANK MA: Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology (2000) 119:631–638.
   PubMed Web of Science ®Google Scholar
• LEDER BZ, KRONENBERG HM: Gastroenterologists and choosing the right bisphosphonate. Editorial. Gastroenterology (2000) 119:866–871.
   Google Scholar